Showing 2531-2540 of 3159 results for "".
- Galderma Finalizes Expansion in Aesthetic and Corrective Dermatologyhttps://practicaldermatology.com/news/20140710-galderma_finalizes_expansion_in_aesthetic_and_corrective_dermatology/2459175/Galderma S.A. has gained full rights to distribute Restylane, Perlane, Emervel, Sculptra, and Dysport from Valeant Pharmaceuticals International, Inc. “We at Galderma are delighted to bring Restylane, Perlane, Emervel, and Dysport home in the U.S. and
- Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billionhttps://practicaldermatology.com/news/20140528-valeant_pharmaceuticals_to_sell_filler_and_toxin_assets_to_nestle_for_14_billion/2459228/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquis
- Pliaglis Launches in Europehttps://practicaldermatology.com/news/20130502-pliaglis_launches_in_europe/2459551/Nuvo Research Inc. and Galderma Pharma, S.A. launched Pliaglis (lidocaine and tetracaine) Cream 7%/7% in Europe. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, and licenses have been issued in 14 of the 16 European cou
- Galderma Acquires Spirighttps://practicaldermatology.com/news/20121213-galderma_acquires_spirig/2459659/Galderma Pharma S.A. and Spirig Pharma A.G. entered into a definitive agreement under which Galderma will acquire Spirig. Spirig's products treat conditions such as solar damage, skin barrier function impairment, and actinic keratosis. Leading br
- Valeant, Galderma Revise Agreement Termshttps://practicaldermatology.com/news/20121210-valeant_galderma_revise_agreement_terms/2459661/Valeant Pharmaceuticals International, Inc. reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and co
- Jeffrey T. S. Hsu, MD, FAADhttps://practicaldermatology.com/profiles/jeffrey-t-s-hsu-md-faad/74v190/
- Jeffrey M. Weinberg, MDhttps://practicaldermatology.com/profiles/jeffrey-m-weinberg-md/L6KQEX/
- Jeffrey Fromowitz, MDhttps://practicaldermatology.com/profiles/jeffrey-fromowitz-md/LqN4kW/
- Jeffrey Rapaport, MDhttps://practicaldermatology.com/profiles/jeffrey-rapaport-md/jVVKp6/
- Jeffrey Dover, MDhttps://practicaldermatology.com/profiles/jeffrey-dover-md/L8YDoY/